Sign in to view content

Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD

Neil M. Bressler, MD

Video
Published 2022

Related

The Cilioretinal Artery is Protective Against Choroidal Neovascularization in Age-Related Macular Degeneration
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2018
Imaging Pearls in AMD
Netan Choudhry, MD, FRCS(C) FASRS
Glenn J. Jaffe, MD
Member Podcasts
Efficacy and Safety of Biosimilar Ranibizumab-nuna and Ranibizumab-eqrn in Clnical Use by a Consortium of Retina Specialists
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more